Verily Raises $300 Million as Alphabet Steps Back From Controlling Stake
Verily Health Inc., the health technology company spun out from Alphabet's X Development, closed a $300 million funding round led by Series X Capital on March 19. The investment marks a structural shift: Alphabet remains a significant minority investor but no longer holds a controlling stake in the company.
The funding round included participation from UCHealth, the University of Colorado Anschutz, and other investors. Verily has reorganized from a limited liability company into a traditional corporation.
Strategy Shift Toward AI-Ready Data
Verily plans to use the capital to advance its precision health AI platform, which helps healthcare organizations standardize and prepare their data for machine learning applications. The company has framed this as making healthcare data "AI-ready" - a prerequisite for deploying algorithms into clinical and research workflows.
Stephen Gillett, Verily's chairman and CEO, said the funding enables the company to combine "clinical and scientific rigor together with AI to deliver the next generation of healthcare."
Recent Commercial Partnerships
Verily has announced several partnerships in recent months. Samsung's Galaxy Watch will integrate with Verily's Pre platform to support biomarker development in clinical research. Salesforce will integrate Verily's Pre platform with its Agentforce Health product for enterprise precision health solutions.
UCHealth and the University of Colorado Anschutz are using the Pre platform for research and care transformation, a collaboration that helped attract the university as an investor.
Alphabet's Continued Involvement
Ruth Porat, Alphabet's president and chief investment officer, said the company supports Verily's approach to addressing "longstanding challenges in the healthcare industry" through technology. She characterized the new investor group as enabling Verily to scale while Alphabet maintains involvement.
Verily graduated from Google X a decade ago as one of Alphabet's earliest "Other Bets" focused on breakthrough science and health innovation.
Research Applications
Kimberly Muller, vice chancellor for innovation and biotechnology at CU Anschutz, said the partnership would allow the institution to "generate insights into disease that we never could have before" and accelerate translating discoveries into treatments.
Richard Zane, UCHealth's chief medical and innovation officer, described the data framework as creating "a generational opportunity" for personalized medicine at the health system level.
For researchers and scientists, the platform's value lies in standardizing how health data flows into analysis pipelines - reducing the time spent on data preparation before running experiments or training models.
Learn more about AI for Science & Research or explore AI for Healthcare applications.
Your membership also unlocks:
